Zenkuda and Tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD
Zenkuda Demonstrates a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval in wAMD
Mechanistic Support for Ocular Intracellular Drug Delivery: Receptor-Mediated Uptake and Trafficking of Antibody Biopolymer Conjugates (ABC®) in Primary Endothelial Cells